January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? – Paolo Tarantino
Jul 28, 2023, 08:26

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? – Paolo Tarantino

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support?

Which one should be utilized first? Find the answer in our latest letter to the editor, now published on Annals of Oncology, Giuseppe Curigliano, Sara Tolaney.

Click here for full article.